Sotera Health Company (SHC)
Valuation Overview•Is Sotera Health Company Overvalued or Undervalued?
Trading at a discount across both intrinsic cash flow and relative peer multiples, indicating a strong margin of safety.
Moderate quality score of 63/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Solid fundamental quality, though solvency presents a headwind.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. The company currently retains all capital for reinvestment and growth rather than returning it to shareholders.
SHC demonstrates strong business quality with robust profitability and healthy margins. However, the balance sheet carries elevated leverage, requiring careful monitoring of debt servicing capabilities.
The company demonstrates solid revenue growth (5.1% 3Y CAGR) paired with stable bottom-line earnings. This growth is supported by elite operational efficiency, sustaining an impressive 34.9% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $280.0M | +5.7% | +5.1% | +7.3% | — | |
| EBITDA | $78.9M | — | -8.4% | — | — | |
| Net Income | $26.6M | +75.6% | — | — | — | |
| EPS (Diluted) | $0.09 | +68.8% | — | — | — | |
| Free Cash Flow | $0.00 | +230.8% | +16.0% | +17.3% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 55.3% | 55.1% | 55.3% | 53.7% |
| Operating Margin | 34.9% | 29.1% | 27.9% | 24.9% |
| Net Margin | 9.9% | 5.2% | 1.0% | -0.4% |
| FCF Margin | 9.4% | -5.9% | 2.2% | 4.7% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.17 | $0.18 | +5.9% | ||
| Q1'26 | $0.24 | $0.26 | +8.3% | ||
| Q4'25 | $0.22 | $0.26 | +18.2% | ||
| Q3'25 | $0.17 | $0.20 | +17.6% | ||
| Q2'25 | $0.12 | $0.14 | +16.7% | ||
| Q1'25 | $0.21 | $0.21 | +0.0% | ||
| Q4'24 | $0.19 | $0.17 | -10.5% | ||
| Q3'24 | $0.17 | $0.19 | +11.8% |
Total return is +44.6% (1Y), outperforming the benchmark by +19.6%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -10.6% | -19.9% | — |
| 1Y | +44.6% | +19.6% | — |
| 3YCAGR | +1.8% | -18.5% | — |
| 5YCAGR | -7.5% | -20.8% | — |
| 10YCAGR | -4.5% | -18.4% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Sotera Health Company (SHC) valuation, health, and returns.
Sotera Health Company is estimated to be undervalued under our discounted cash flow framework. relative multiples indicate the stock is Cheap versus peers compared to industry peers. undervalued (implying +18.2% upside to DCF intrinsic value of $18.70)
Sotera Health Company has multiple valuation anchors: DCF Intrinsic Value: $18.70 | Peer Relative Fair Value: $23.13 | Wall Street Analyst Target: $21.50 (implying +35.9% upside). A convergence of these signals offers higher conviction.
Sotera Health Company displays good financial health with a composite quality score of 63/100, supported by a Altman Z-Score of 0.8 (distress zone), Piotroski F-Score of 6/9, Return on Invested Capital (ROIC) of 11.8%.
Sotera Health Company does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Sotera Health Company's current growth trajectory is Stable. The company achieved +5.7% 1Y revenue growth and +68.8% 1Y EPS growth, compared to its 3Y revenue CAGR of +5.1%.
Wall Street consensus is Buy based on 12 analysts, beating EPS expectations in 58% of recent quarters with a 5-quarter streak. The consensus price target represents a +35.9% change from current levels.
Investment risks for Sotera Health Company include: -32.1% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 1.27x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.